'Critical questions' overlooked in new US guidance on mobile medical apps
This article was originally published in Clinica
Executive Summary
The final guidance document that the US FDA issued in September to help developers of mobile applications, or apps, determine whether or not their products should be regulated as medical devices leaves open some "critical questions".